Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc. (MNMD) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
mnmd · stock forecast · 1 analysts (3M) · FMP · updated Apr 3, 2026
Analyst Rating & Consensus
Based on 1 Wall Street analysts in the past 3 months
Buy
1 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$28.00
Consensus
$20.00
-8.6% upside
Low
$14.00
Median: $20 · Last Close: $21.88
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$20.00
-8.6% upside
High Target
$28
28.0%
Low Target
$14
-36.0%
Current Price
$21.88
as of today
Based on analyst price targets, the MNMD stock price prediction for the next 12 months ranges from $14 to $28. The consensus MNMD price forecast of $20.00 implies -8.6% upside from the current price of $21.88.
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $21.45 | ↓ 1.95% |
1-day model range: $21.31–$21.59. Peak: $21.59 (-1.95%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $38 | +71.8% |
| 2028 | $52 | +139.7% |
| 2029 | $64 | +191.7% |
| 2030 | $71 | +226.6% |
| 2031 | — | +248.0% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · MNMD · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|
Wall Street analysts have recently issued updated ratings on Mind Medicine (MindMed) Inc. (MNMD) stock. Of the recent 0 rating actions, 0 were upgrades and 0 were downgrades. 1 analysts currently cover MNMD.
Analyst Recommendation Trends
MNMD analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$17M
↓ 92.3% YoY
Revenue Next Year
$56M
↑ 236.0% YoY
EPS This Year
$-1.94
EPS Next Year
$-1.82
↓ 6.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast MNMD EPS of $-1.94 for the current fiscal year, based on estimates from 9 analysts. The MNMD revenue forecast is $17M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The MNMD stock forecast is supported by two independent data sources: analyst consensus ratings from 1 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus MNMD price target is $20.00 (-8.6% upside), with an analyst consensus of Buy.
The MNMD short-term stock prediction for tomorrow is $21.45 (-1.95%). The MNMD stock price prediction for 2027 estimates an average of $38. The MNMD stock prediction for 2030 projects a range of $66–$77.
Mind Medicine (MindMed) Inc. trades on NASDAQ under the ticker MNMD. The MNMD stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
MNMD forecast · 8 questionsAccording to 1 Wall Street analysts, the average 12-month MNMD price target is $20.00, with a high forecast of $28.00 and a low of $14.00. The median price target is shown in the chart above when available. This implies -8.6% potential upside from the current price of $21.88.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.